EU Guidance Explains How And When MDSAP Audits Can Offer Auditing Shortcuts

This is the busiest time in the history of notified bodies as they try to process all manufacturers under the EU Medical Device Regulation (MDR). Making use of MDSAP audits is one way to cut down on work but is not always an option. The EU’s latest guidance explains the detail.

Woodland_Path
What Is MDSAP And When Are the Reports Useful In The EU?

The Medical Device Single Audit Program (MDSAP) allows manufacturers to have their medical device quality management system audited once as testimony that it meets the quality system regulatory requirements of up to five different medical device markets: Australia, Brazil, Canada, Japan and the US.

As would be expected, the use of MDSAP audit reports within the EU legislative framework is possible only where the MDSAP audit covers similar or equivalent MDR/IVDR requirements.

Whatever is contained in the MDSAP report, notified bodies have the full authority over their judgement, conclusion and final decision about the conformity of quality management systems under the MDR/IVDR and the safety and performance of medical devices and IVDs intended to be placed on the market in the EU.

A new 10-page EU guidance,

This information will be of particular use in cases where a manufacturer has undergone an MDSAP audit and wishes to present this audit report (including the associated attachments) to a notified body so that it can be

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

More from Geography

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.